<DOC>
	<DOCNO>NCT00004931</DOCNO>
	<brief_summary>Randomized phase III trial compare effectiveness fluorouracil plus leucovorin without oxaliplatin treat patient stage II stage III colon cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective colon cancer</brief_summary>
	<brief_title>Fluorouracil Plus Leucovorin With Without Oxaliplatin Treating Patients With Stage II Stage III Colon Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare relative efficacy 5-FU + LV + Oxaliplatin ( FLOX ) 5-FU + LV ( FL ) prolong DFS . SECONDARY OBJECTIVES : I . To compare relative efficacy FLOX FL prolong S. OUTLINE : This randomize study . Patients randomize one two treatment arm . ARM I : Patients receive leucovorin calcium IV 2 hour fluorouracil IV ( administer 1 hour leucovorin calcium ) weekly 6 week . ARM II : Patients receive oxaliplatin IV 2 hour day 1 , 15 , 29 leucovorin calcium fluorouracil arm I . Treatment arm repeat every 8 week 3 course absence disease progression unacceptable toxicity . Patients follow 6 , 9 , 12 month ; every 6 month 4 year ; annually thereafter .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Patients must consent study must sign date IRBapproved consent form conform federal institutional guideline In opinion investigator , patient must 10year life expectancy , exclude diagnosis cancer The interval curative resection randomization must 42 day The distal extent tumor must &gt; = 12 cm anal verge endoscopy Patients must colonic adenocarcinoma meet one criterion : Stage II carcinoma ( T3 , 4 ; N0 ; M0 ) The tumor invade muscularis propria subserosa , nonperitonealized pericolic perirectal tissue ( T3 ) directly invade organ structure , and/or perforate visceral peritoneum ( T4 ) , exclude free perforation Stage III carcinoma ( T ; N1 , 2 ; M0 ) The tumor invade depth , involvement regional lymph node AGCs &gt; = 1500/mm^3 Platelets &gt; = 100,000/mm^3 Bilirubin within normal limit laboratory Alkaline phosphatase within normal limit laboratory SGOT SGPT within normal limit laboratory Serum creatinine within normal limit laboratory Patients one synchronous primary colon tumor eligible ; purpose protocol , stag classification base stage advance primary tumor Patients eligible adjacent structure ( e.g. , bladder , small intestine , ovary , etc . ) involve direct extension primary tumor remove en bloc , judgement surgeon confirmation histological examination ( i.e. , margin resection involve ) , resection deem `` curative '' Patients must ECOG performance status 0 , 1 , 2 Patients intestinal obstruction eligible ; preliminary complementary colostomy preclude entry Patients prior noncolorectal malignancy eligible diseasefree &gt; = 5 year ; patient squamous basal cell carcinoma skin effectively treat , carcinoma situ cervix treat operation , lobular carcinoma situ breast eligible , even condition diagnose within 5 year prior randomization Prior invasive colon rectal malignancy , regardless diseasefree interval Current past malignant colon tumor carcinoma , i.e. , sarcoma , lymphoma , carcinoid , etc. , regardless diseasefree interval Tumors locate &lt; 12 cm anal verge preoperative endoscopy Tumors demonstrate free perforation manifest free air free fluid abdomen ; patient walledoff perforation eligible Pregnancy lactation time propose randomization ; ( 5FU oxaliplatin teratogenic mutagenic may cause fetal harm ; ) eligible patient reproductive potential ( sex ) must agree use adequate contraceptive method Noncurative surgical resection prior chemotherapy radiotherapy malignancy , exception decompress colostomy Nonmalignant systemic disease ( cardiovascular , renal , hepatic , etc . ) would preclude patient 's receive either chemotherapy treatment option ; specifically exclude patient active ischemic heart disease ( class III class IV myocardial disease New York Heart Association ) recent history myocardial infarction ( within 6 month ) , current symptomatic arrhythmia Class III : Patients cardiac disease result marked limitation physical activity ; patient comfortable rest ; lessthanordinary physical activity cause fatigue , palpitation , dyspnea , anginal pain Class IV : Patients cardiac disease result inability perform physical activity without discomfort ; symptom cardiac insufficiency anginal syndrome may present even rest Psychiatric addictive disorder would preclude obtain informed consent Multiple primary tumor involve colon rectum would preclude patient 's classified colon cancer Evidence laparoscopicallyassisted colectomy , unless patient participate Intergroup Protocol INT 0146 Australasian , Multicenter , Prospective , Randomized , Clinical Study Comparing Laparoscopic Conventional Open Surgical Treatments Colon Cancer Adults ( ALCCaS ) Isolated , distant , noncontiguous intraabdominal metastasis , even resect , render patient ineligible Clinically significant peripheral neuropathy time randomization ( defined NCI Common Toxicity Criteria [ CTC ] grade 2 great neurosensory neuromotor toxicity )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>